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ABSTRACT
Introduction: Globally, individuals with
asthma tend to overrely on short-acting b2-ag-
onists (SABAs) and underuse inhaled corticos-
teroids, thereby undertreating the underlying
inflammation. Such relief-seeking behavior has
been reinforced by long-standing treatment
guidelines, which until recently recommended
SABA-only use for immediate symptom relief.
We aimed to describe the current burden of
SABA use among European individuals with
asthma within the SABA use IN Asthma
(SABINA) program.
Methods: Prescription and/or dispensing data
during 2006–2017 from electronic medical
records and/or national patient registries in the
United Kingdom (UK), Germany, Italy, Spain,
and Sweden were analyzed. Individuals aged at
least 12 years old with a current asthma diag-
nosis and no other chronic respiratory condi-
tions were included. Asthma treatment step and
severity were based on treatment guidelines in
use in each individual country. The proportion
of individuals prescribed SABA was measured
during a 12-month period. SABA overuse was
defined as at least three SABA canisters per year.
Results: More than one million individuals
with asthma were included across five European
countries. Overall, the majority of individuals
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were over 45 years of age, except in Sweden
(mean age 27.6 years) where individuals aged
over 45 years were excluded to avoid a potential
chronic obstructive pulmonary disease co-diag-
nosis. The study population was predominantly
female (55–64%), except in the UK (46%). The
prevalence of SABA overuse was 9% in Italy,
16% in Germany, 29% in Spain, 30% in Sweden,
and 38% in the UK. In the UK, SABA overuse
was greater in individuals with moderate-to-
severe asthma versus individuals with mild
asthma (58% versus 27%, respectively), while
SABA overuse was similar in individuals with
both mild (9–32%) and moderate-to-severe
(8–31%) asthma in the other European
countries.
Conclusions: The findings of this study from
the SABINA program show that SABA overuse
(at least three canisters per year) is common
across Europe, despite the different healthcare
and reimbursement policies of each country.
Keywords: Europe; Overreliance; Prescription;
Public health; Short-acting b2-agonist
Key Summary Points
Why carry out this study?
Despite the availability of effective asthma
treatments, some individuals are poorly
controlled because of overreliance on
short-acting b2-agonists (SABAs) and
underuse of inhaled corticosteroids.
As a result of growing evidence that SABA
overreliance is associated with an
increased risk of asthma-related
exacerbations and mortality, a global view
of SABA prescriptions is needed to better
understand the public health burden of
SABA overuse in asthma management.
As part of the SABINA (SABA use IN
Asthma) program, this study aimed to
provide an overview of similarities and
differences in SABA prescription trends
across five European countries (UK,
Germany, Italy, Spain, and Sweden) in
over one million individuals.
What was learned from the study?
SABA overuse (C 3 canisters per year)
occurred in approximately one-third of
mild, moderate, and severe individuals
with asthma across Europe, despite the
different healthcare and reimbursement
policies of each country.
These findings indicate that there is a
significant group of individuals who are
not optimally treated according to current
recommendations.
Following the recent 2019 Global
Initiative for Asthma (GINA) update,
which no longer recommends treating
adolescents and adults with as-needed
SABA alone for symptom relief, changes in
physician and patient behaviors towards
SABA use, and updates to national
healthcare policies, are required to ensure
that individuals with asthma are not
exposed to SABA alone in the treatment of
their asthma.
INTRODUCTION
Asthma is a chronic, heterogeneous, fluctuat-
ing, inflammatory disease of the airways that is
estimated to affect 339 million people world-
wide [1]. In Europe, over 8% of adults have
asthma, with the highest prevalence found in
the United Kingdom (UK) and Sweden [1–3].
Anti-inflammatory maintenance treatment
with low-dose inhaled corticosteroids (ICS) is
the cornerstone of asthma treatment [4]. As-
needed short-acting b2-agonists (SABAs) have
been traditionally prescribed for symptom
relief, with or without daily maintenance
treatment, depending on the level of asthma
severity [5, 6]. However, evidence on the safety
risks associated with high SABA use has grown
substantially in the last few years [7–10]. In
parallel, clinical trials have reported the superi-
ority of anti-inflammatory reliever therapy with
as-needed ICS–formoterol versus as-needed
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SABA in terms of symptom control and reduc-
tion in exacerbation risk [11–15]. Consequently,
the 2019 Global Initiative for Asthma (GINA)
recommendations have eliminated SABA
monotherapy in step 1 and instead recommend
as-needed low-dose ICS–formoterol as the pre-
ferred reliever in steps 1–2. In addition, in GINA
steps 3–5, low-dose ICS–formoterol is the pre-
ferred reliever for patients prescribed ICS–for-
moterol maintenance and reliever therapy [16].
With this knowledge, SABA overreliance is
now an even greater concern. However, it will
be difficult to change this overreliance, linked
to decades of patient behavior and guidelines
recommending, until very recently, SABA use
for immediate symptom relief and as the first
treatment for newly diagnosed mild intermit-
tent asthma [17, 18]. When symptoms worsen,
most individuals with asthma overrely on their
SABA inhaler for symptomatic relief, often at
the expense of ICS maintenance therapy
[19–21]. As SABAs have no anti-inflammatory
effect [22, 23], they neither treat the underlying
inflammation nor protect against exacerba-
tions. The continued reliance on SABA relievers
leaves individuals across all asthma severities at
risk of preventable attacks whether adherent or
not to their maintenance controller [11, 14].
Indeed, in the UK, SABA overuse and the rela-
tive underuse of ICS was highlighted as one of
the underlying reasons for preventable asthma
attacks and deaths [24].
There are limited data on SABA and ICS
prescription trends in European countries, and a
pan-European view of potential SABA overuse
and relative ICS underuse is lacking. The SABA
use IN Asthma (SABINA) program [25] was
therefore initiated to describe the global extent
of SABA and ICS use in asthma and its clinical
consequences. For the purpose of this analysis,
which was to understand the current state of
asthma reliever prescriptions relative to recent
treatment recommendations, we aimed to pro-
vide an overview of the similarities and differ-
ences in SABA prescription trends only, for




The SABINA program encompasses three main
pillars: SABINA I (a retrospective, observational
database study with expanded objectives in the
UK), SABINA II (a distributed harmonized set of
multicountry retrospective observational data-
base studies in Europe and Canada), and
SABINA III (a prospectively collected multi-
country cross-sectional study in 25 countries).
Full details of the SABINA program are described
elsewhere [25]. In this study, prescription data
generated from the European arms of SABINA—
SABINA I (UK) and SABINA II (Italy, Germany,
Spain, and Sweden)—were analyzed. On the
basis of data availability, individual country
data were obtained from electronic medical
records and/or national patient registries as
shown in Table 1.
Patient Population
Individuals aged at least 12 years old with a
current asthma diagnosis were included in the
study. In Sweden, the study population inclu-
ded all individuals with asthma who collected
at least two drugs for obstructive lung disease
(ATC R03) from pharmacies in a 1-year period.
In addition, the upper age limit of 45 years was
applied in Sweden to ensure that individuals
with chronic obstructive pulmonary disease
(COPD) were excluded, a validated proxy for
asthma [26]. The definition of current asthma
varied across studies (Table 1). For instance, in
most countries, current asthma was defined as
an asthma diagnosis code within 1 or 3 years
before the index date (date on which the indi-
vidual first entered the study); however, in
Sweden, it was defined as at least two prescrip-
tions for a chronic obstructive lung disease
medication within 12 months of study entry.
All studies required individuals with asthma to
have data for at least 12 months before and after
study entry. Study periods varied between 2006
and 2018. However, all countries included
recent data (2016–2018) on SABA use, while
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some countries, such as Sweden and the UK,
included data from as early as 2006.
The studies performed as part of the SABINA
program were each approved by the institu-
tional review board of the ethics committee in
their individual country and were conducted in
accordance with the Declaration of Helsinki of
1964 and its later amendments, the Interna-
tional Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human
Use (ICH), Good Clinical Practice (GCP), and
the applicable legislation on non-interventional
studies and/or observational studies.
Study Measures
SABA Use
The percentage of individuals with asthma who
were prescribed SABA was recorded during a
12-month period. SABA use was categorized by
the number of canister prescriptions per year
(0–2, 3–6, 7–12, or 13 and more). According to
the guidelines, appropriate use of SABA is con-
sidered as fewer than three puffs per week,
which is equivalent to fewer than 150 puffs/
actuations per year or at most two prescribed
canisters per year. For consistency across all
countries in the SABINA program, one SABA
canister was assumed to contain 150
Table 1 Study design features in SABINA I and II
SABINA I (UK) SABINA II
Germany Italy Sweden Spain
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inhalations [25]. However, in Germany and
Spain, one canister was defined as containing
200 inhalations based on a preliminary analysis
of the data, which showed that nearly all pre-
scribed SABA canisters contained 200 doses. On
the basis of this assumption and allowing for
individuals to have multiple SABA inhalers at
the same time, SABA overuse was defined as
prescription/dispensing of at least three canis-
ters per year.
Treatment Step and Asthma Severity
Individuals with asthma were categorized into
treatment steps (1–5) and severity (mild,
steps 1–2; moderate–severe, steps 3–5) by their
ICS prescriptions (low, medium, or high) in the
year prior to their index date on the basis of the
2016 British Thoracic Society (BTS) guidelines
[6] (low-dose ICS, 400–799 lg beclometasone
dipropionate [BDP] equivalent; medium-dose
ICS, 800–1599 lg; high-dose ICS, at least
1600 lg) for the UK or 2018 GINA recommen-
dations [5] (low-dose ICS, 200–500 lg BDP
equivalent; medium-dose ICS, 500–1000 lg BDP
equivalent; high-dose ICS, more than 1000 lg
BDP equivalent) for the remaining countries.
Statistical Analysis
Baseline characteristics were described as mean
(standard deviation, SD) for continuous vari-
ables and absolute and relative frequencies for
categorical variables. Descriptive statistics were
provided for the SABA prescription data.
Table 2 Baseline characteristics of individuals with asthma
Italy Germany Spain Sweden UK
Total number of included individuals with asthma 22,102 53,866 39,555 365,324 574,913










Male gender (%) 42 40 36 45 54
Individuals with mild asthma (treatment stepa 1–2) (%) 37 60 27 48b 65
Individuals with moderate-to-severe asthma (treatment stepa 3–5) (%) 63 40 73 50 35
BTS British Thoracic Society, GINA Global Initiative for Asthma, SD standard deviation
a Treatment steps were based on GINA 2018 for all countries, except the UK (BTS 2016)
b Approximately 2% of individuals could not be classified into a GINA therapy step in Sweden
Table 3 Treatment characteristics: overall SABA use
Italy Germanya Spain Sweden UK
Mean (SD) number of annual SABA canisters 3.1 (4.0) 1.6 (3.9) 3.3 (3.6) 1.9 (2.9) 4.2 (5.1)
Individuals with 0–2 SABA canisters/year (%) 91 84 71 70 62
Individuals with C 3 SABA canisters/year (%) 9 16 29 30 38
Individuals with 3–6 SABA canisters/year (%) 6 10 19 25 24
Individuals with 7–12 SABA canisters/year (%) 2 3 6 5 11
Individuals with C 13 SABA canisters/year (%) 1 2 4 1 4
GP general practitioner, SABA short acting b2-agonist, SD standard deviation
a This analysis was based on GP-treated individuals only (n = 29,636)




Overall, 1.06 million individuals with asthma
were included across the countries. On average,
most individuals were at least 45 years of age,
except in Sweden where the mean age of indi-
viduals was 27.6 years (Table 2). Most individu-
als with asthma were female, except in the UK,
where male individuals constituted the majority
(54%). The severity of asthma (as determined by
treatment step) varied across countries. In Ger-
many and the UK, most of the study population
included were treated as having mild asthma
(60% and 65%, respectively). In Italy and Spain,
most individuals had moderate-to-severe
asthma (63% and 73%, respectively), while in
Sweden, they were distributed almost equally
across severities.
SABA Use
The characteristics of SABA use are summarized
in Table 3 and Fig. 1. The mean number of
annual SABA canisters used varied across coun-
tries. Overall, the prevalence of SABA overuse
was 9% in Italy, 16% in Germany, 29% in Spain,
30% in Sweden, and 38% in the UK. In the UK,
SABA overuse was greater in individuals with
moderate-to-severe asthma versus mild asthma
(58% versus 27%). Overall, SABA overuse was
similar in individuals with mild (9–32%) and
moderate-to-severe (8–31%) asthma in the
other European countries.
DISCUSSION
SABINA I and II assessed SABA prescription
trends across European countries in over a mil-
lion individuals with asthma. Overall, with the
exception of Italy, SABA use was common
across all asthma severities, and our data suggest
that approximately one-third of individuals are
overusing SABA.
Our findings are generally consistent with
those of other studies in a European population
using the same SABA canister cutoff, but dif-
ferent study designs. In the cross-sectional
ASTHMAPOP survey among 15,587 adults in
France, 28.3% of patients reported using at least
three SABA canisters per year [27]. Similarly, a
Polish study of pharmacy prescription records
of 91,673 adult patients observed that 29–37%
of patients with asthma were prescribed at least
Fig. 1 SABA use in individuals with mild and moderate-
to-severe asthma across European countries. In Germany,
analysis was based on GP-treated individuals only
(n = 29,636). Treatment steps were based on GINA
2018 for all countries, except the UK (BTS 2016). BTS
British Thoracic Society, GINA Global Initiative for
Asthma, GP general practitioner, SABA short-acting b2-
agonist
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three SABA canisters per year [28]. Differences
in national healthcare and medication reim-
bursement policies may impact medication
prescribing practices and related clinical out-
comes, and this needs to be taken into consid-
eration for the present study findings. For
instance, SABA is available without a prescrip-
tion in Italy, Spain, and the UK (emergency
access only), but not in Germany and Sweden.
Notably, availability of SABA without a pre-
scription has been linked to undertreatment of
asthma (relative to the relevant guidelines rec-
ommendations) and infrequent consultations
with physicians [29]. Moreover, it has been
shown that without regular medical supervi-
sion, patients are more likely to overuse SABA
[30]. Although SABA medication is not available
without a prescription in many countries in the
SABINA program, such findings have far-reach-
ing global implications. Consequently, an
improved understanding of this population of
individuals with asthma who purchase SABA,
especially their attitudes and beliefs about
asthma and its treatment, is essential. A recent
real-world, cross-sectional observational study
in Australia, where SABA medication can be
purchased from the community pharmacist
without a prescription, identified a cohort of
individuals with suboptimal asthma control, co-
existing allergic rhinitis, and poor ICS adher-
ence who were SABA overusers (used SABA more
than twice a week in the past 4 weeks) [31].
Addressing such findings in primary care is
critical to address the issue of SABA overuse.
Because the availability of SABA without pre-
scription was not taken into account in our
analysis, actual SABA use may be even higher in
countries that do not require a prescription to
purchase SABA medication. This finding is par-
ticularly apparent in the assessment of SABA
prescriptions in Italy in our study, where SABA
overuse was less evident compared with other
European countries. From initial market
research, it is understood that a relatively large
proportion of individuals with asthma obtain
SABA inhalers without prescription, which
could explain the low prevalence of SABA
overuse in prescription databases. Further anal-
yses are now planned to investigate this possi-
bility in Italy.
Although similar SABA use trends were
observed despite differences across national
policies, data sources, and study designs, there
were some differences in relation to SABA use
and asthma severity. Among the five countries
analyzed, the UK had the lowest percentage of
individuals receiving treatment for moderate-
to-severe asthma, and the highest average
number of annual SABA prescriptions. This
could indicate that individuals with uncon-
trolled asthma in the UK are more likely to be
prescribed SABA rather than being reviewed and
prescribed an increased dose of their mainte-
nance therapy as recommended by guidelines
[6]. Indeed, according to a recent survey among
individuals with asthma in the UK, over 60% of
respondents indicated that they did not receive
basic asthma care, and approximately 20% of
respondents did not receive an annual asthma
review [32].
Exposure and adherence to maintenance ICS
will likely impact SABA use, and it is, therefore,
important to put these findings into the context
of ICS exposure. SABA overuse was greater in
individuals with moderate-to-severe asthma (up
to 58%) compared with individuals with mild
asthma, suggesting a greater degree of poor
asthma control in these individuals despite
receiving maintenance ICS to treat the under-
lying inflammation. Similar results were repor-
ted from the recent Polish pharmacy
prescription study, in which patients on a
higher treatment step received more SABA pre-
scriptions compared with patients on lower
treatment steps [28]. It is possible that low ICS
adherence is a driving factor or that mainte-
nance therapy exposure is simply an indication
of disease severity and of an increased likeli-
hood of the presence of symptoms that require
SABA. More detailed analyses in the individual
SABINA studies are underway to investigate the
potential association of ICS and SABA use.
Overall, our findings indicate that there is
considerable SABA use—and indeed SABA
overuse—among individuals across Europe,
which puts them at risk of adverse outcomes.
Changes in physician and patient behaviors
towards SABA use, active engagement in
adapting 2019 GINA recommendations to local
guidelines, and updates to national healthcare
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policies will be needed to ensure that individu-
als with asthma are not unnecessarily exposed
to SABA alone in the treatment of their
inflammatory disease. Physicians should
encourage the appropriate use of ICS, eliminate
SABA monotherapy as per evidence-based rec-
ommendations, challenge patient attitudes and
practices around SABA use, and ensure that
individuals understand that asthma is an
inflammatory condition. Importantly, individ-
uals should be trained on the appropriate use of
therapy [33] and the technical use of inhalers
[34]. Asthma education programs discouraging
unregulated SABA use should be given due
consideration. Education, together with regular
medical reviews and written personal asthma
action plans, is advocated in guidelines and has
been shown to improve health outcomes for
individuals with asthma [35]. Therefore, a drive
to implement personal actions plans, describing
how patients may recognize a deterioration in
asthma control and what steps should be taken
to re-establish control [36], could further assist
in curbing SABA overuse. Other healthcare
professionals, such as nurses and pharmacists,
could also provide training and support to
patients. Pharmacists can also play an integral
role as they are in the unique position of being
able to initiate conversations about SABA over-
use and can spend time educating patients and
answering any questions [31].
Potential limitations of this analysis relate to
the observational nature of the included studies
and the use of medical databases that were not
necessarily designed for research purposes.
However, the results were comparable to those
from the UK arm of SABINA, which used
research-quality data from the Clinical Practice
Research Datalink [37]. This increases confi-
dence in the robustness of the data across the
rest of the countries. Additionally, the upper
age limit of 45 years in Sweden may have led to
more individuals with severe asthma being
excluded from the analysis. However, the algo-
rithm that was used to identify individuals with
asthma based on pharmacy collection of drugs
(ATC R03) for obstructive lung disease was
shown to be a suitable proxy for asthma diag-
nosis in this age group in validation studies
from Sweden [26]. This restriction was not
necessary in other countries, where other vali-
dated algorithms were used (e.g., the UK) [38],
and where sensitivity analyses were conducted
to exclude individuals with a COPD co-diagno-
sis. Despite these differences, similar overall
trends were seen across the countries, indicating
that the age restriction applied to Sweden may
have had limited impact on the results. Of note,
dispensed or prescribed SABA may not always
equal the medication taken and may lead to an
overestimation of actual SABA overuse. Auto-
matic repeat prescriptions, or simultaneous
prescriptions of multiple SABA canisters, may
result in individuals having more SABA inhalers
in their possession, which they may not neces-
sarily use. From clinical experience, we know
that individuals with asthma typically have
multiple SABA inhalers such that there is at least
one inhaler in each of their surroundings (e.g.,
home, office, car). This is done so that individ-
uals with asthma have immediate access to their
reliever in the event of a sudden worsening in
symptoms. Despite these limitations, the cur-
rent manuscript assessed a large asthma popu-
lation across five countries and provides
important insights regarding SABA use and the
extent of SABA overuse. The use of standardized
thresholds for SABA overuse in the SABINA
program enabled comparisons across countries,
which were previously limited by the varying
SABA overuse thresholds used across published
studies [39–41]. The next steps for the program
are to describe SABA use across additional
countries, and to investigate the association of
SABA use, maintenance ICS therapy, and clini-
cal outcomes with healthcare resource use.
Additionally, further context around patient’s
quality of life and patient’s adherence behaviors
will provide important insights into how to
better interpret the program findings and how
to potentially decrease SABA use in the future.
More in-depth analyses should be performed in
those countries that are involved in the SABINA
program.
CONCLUSIONS
There is a growing body of evidence that high
SABA use is associated with increased risk of
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adverse asthma-related outcomes. Individuals
across all asthma severities remain at risk of
exacerbations when they continue to overrely on
SABA at the expense of ICS, leaving the underly-
ing inflammation undertreated. Data from the
SABINA program demonstrated that a consider-
able proportion of individuals with asthma across
Europe are using at least three SABA canisters per
year, indicating that there is a significant group of
individuals who are currently not optimally trea-
ted according to the 2019 GINA recommenda-
tions. The combination of an ICS/fast-onset but
long-acting b2-agonist will be an effective patient-
friendly strategy for improving adherence to evi-
dence-based guidelines. Further work to support
changes to national treatment guidelines and,
therefore, ensure successful implementation of
the latest GINA recommendations is currently
underway.
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